Clinical Updates in Sexually Transmitted Infections, 2024.
| Autor: | Hufstetler, Kaitlin, Llata, Eloisa, Miele, Kathryn, Quilter, Laura A. S. |
|---|---|
| Předmět: |
PREVENTION of sexually transmitted diseases
EPIDEMIOLOGY of sexually transmitted diseases SYPHILIS epidemiology PELVIC inflammatory disease treatment TRICHOMONIASIS treatment SEXUALLY transmitted disease treatment SEXUALLY transmitted disease diagnosis SEXUALLY transmitted diseases MEDICAL protocols MEDICAL history taking CHLAMYDIA HUMAN sexuality SEX education SYPHILIS GONORRHEA MONKEYPOX WOMEN'S health MEDICAL screening PREGNANCY complications MYCOPLASMA diseases SEXUAL health INFECTIOUS disease transmission PREGNANCY |
| Zdroj: | Journal of Women's Health (15409996); Jun2024, Vol. 33 Issue 6, p827-837, 11p |
| Abstrakt: | Sexually transmitted infections (STIs) continue to increase in the United States with more than 2.5 million cases of gonorrhea, chlamydia, and syphilis reported to the Centers for Disease Control and Prevention in 2022. Untreated STIs in women can lead to adverse outcomes, including pelvic inflammatory disease, infertility, chronic pelvic pain, and pregnancy complications such as ectopic pregnancy, early pregnancy loss, stillbirth, and neonatal transmission. STI-related guidelines can be complex and are frequently updated, making it challenging to stay informed on current guidance. This article provides high-yield updates to support clinicians managing STIs by highlighting changes in screening, diagnosis, and treatment. One important topic includes new guidance on syphilis screening, including a clarified description of high community rates of syphilis based on Healthy People 2030 goals, defined as a case rate of primary or secondary syphilis > 4.6 per 100,000. Reproductive aged persons living in counties above this threshold should be offered syphilis screening. Additionally, American College of Obstetricians & Gynecologists now recommends syphilis screening three times during pregnancy regardless of risk—at the first prenatal visit, during the third trimester, and at delivery. In addition, new guidance to support consideration for extragenital screening for gonorrhea and chlamydia in women at sites such as the anus and pharynx is discussed. Other topics include the most recent chlamydia, gonorrhea, trichomoniasis, and pelvic inflammatory disease treatment recommendations; screening and treatment guidance for Mycoplasma genitalium; genital herpes screening indications and current diagnostic challenges; and the diagnosis and management of mpox in women and during pregnancy. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|